Exciting medical research breakthroughs and tips for VTE management, risk assessment and prevention.
A/Prof. Hitos: Exciting Medical Research Breakthroughs in Australia
A/Prof. Hitos: Steps to a Multifaceted Approach to VTE Prevention in Hospitals
Prof. Ward: Improving Rates of VTE Risk Assessment for Medical Patients
LMWH: low molecular weight heparin VTE = venous thromboembolism.
References
1 Clexane Australian Product Information, 13 July 2018.
2 Fareed J et al. Semin Thromb Hemost 2004;30:706–13.
Date of preparation: August 2019. SM_SAN980. SAANZ.ENO.19.01.0069c
*Clexane Safety Lock as an automatic safety lock system.
Further information is available on request from Sanofi.
Please review Product Information before prescribing Clexane. Full Product Information is available by calling 1800 818 806 or by clicking here.
sanofi-aventis australia pty ltd training as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. ®Clexane is a registered trademark of sanofi-aventis.
.png?h=633&la=en&w=1234&hash=F4514235FC2A0801E48EB2FAE2026EBBE6CEC6BD)
Clexane Safety Lock Webinars
Training on how to use Clexane Safety Lock and other resources are available now.

VTEMATTERS.COM.AU
Your patients' information portal for all VTE matters
Password: support
Receive future issues of Anticoagulation Matters, curated specifically for you.
Access patient information and resources on VTE and Clexane®.